Policy roundup: Drug prices and more
نویسندگان
چکیده
منابع مشابه
Regulating Drug Prices: U.S. Policy Alternatives in a Global Context
s of all RAND Health publications and full text of many research documents can be found on the RAND Health web site at www.rand.org/health. This research brief was written by David M. Adamson. The RAND Corporation is a nonprofi t research organization providing objective analysis and effective solutions that address the challenges facing the public and private sectors around the world. RAND’s p...
متن کاملMonetary policy and asset prices
The purpose of this paper is study the effect of monetary policy on asset prices. We study the properties of a monetary model in which a real asset is valued for its rate of return and for its liquidity. We show that money is essential if and only if real assets are scarce, in the precise sense that their supply is not sufficient to satisfy the demand for liquidity. Our model generates a clear ...
متن کاملMonetary Policy and Asset Prices
The rst part of this paper surveys the literature on asset prices and monetary policy. The original contributions begin in section 3. Here we consider how two types of shocks associated with asset prices a ect the economy, and the appropriate policy response. The rst set of shocks are ones whose primary impact lies in the future. These shocks a ect the economy by raising asset prices today. The...
متن کاملAsset Prices and Monetary Policy
This paper studies monetary-policy shocks, de ned from federal funds target movements relative to daily interest-rate data. These shocks are nearly ideal measures of unexpected movements in monetary policy. Market expectations can summarize the vast amount of information used by the Fed in setting policy, and used by Fed-watchers in guessing the Fed’s actions, thus surmounting the omitted-vari...
متن کاملWill lower drug prices jeopardize drug research? A policy fact sheet.
research by large firms, net of taxpayers' subsidies, is paid for out of domestic sales in each country, with profits to spare. Prices can be lower without jeopardizing basic research for new drugs. More exposure to global price competition would encourage more innovative research and less of the derivative me-too research that now dominates. In the U.S., the FDA Commissioner, Mark McClellan, a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacy Today
سال: 2019
ISSN: 1042-0991
DOI: 10.1016/j.ptdy.2019.03.021